| A dual endothelin angiotensin receptor antagonist is being developed by Travere Therapeutics for the treatment of IgA nephropathy and FSGS |
| Received its first approval on 17 February 2023 in the USA under the Accelerated Approval pathway |
| Approved for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.